FindTrial
Sign In

INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES - INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES

INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES - INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-000428-15-FI
Enrollment
400
Registered
2006-01-27
Start date
2006-04-19
Completion date
Unknown
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FRACTURES OF THE FACIAL BONES

Interventions

Trade Name: ORADEXON Product Name: dexamethasone Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: dexamethasone

Sponsors

HANNA THORÉN
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ISOLATED FRACTURES OF THE MANDIBULAR ANGLE OR SYMPHYSIS/PARASYMPYSIS, ZYGOMATIC BONE AND FLOOR OF THE ORBIT. AGE RANGE 18 YEARS OR OLDER Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: LIVER OR RENAL INSUFFICIENCY PEPTIC ULCER PREVIOUS STEROID PSYCHOSIS PREGNANCY NURSING WOMAN

Design outcomes

Primary

MeasureTime frame
Main Objective: TO FIND OUT THE INFLUENCE OF DEXAMETHASONE ON POSTOPERATIVE SWELLING, PAIN AND NAUSEA AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES OF THE MANDIBLE, ZYGOMA OR ORBIT;Secondary Objective: TO REGISTER POSSIBLE ADVERSE EFFECTS OF DEXAMETHASONE IN THE STUDY POPULATION;Primary end point(s):—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026